Monopar Therapeutics Inc. is presenting new data at the AASLD – The Liver Meeting® 2025, showing that treatment with ALXN1840 led to rapid improvement in daily copper balance in Wilson disease patients. The mean daily copper balance among patients treated with ALXN1840 was significantly lower compared to their pre-treatment baseline. Additional data supporting these findings will also be presented. Monopar Therapeutics is a clinical-stage biopharmaceutical company developing treatments for Wilson disease and advanced cancers. For more information, visit www.monopartx.com. Follow Monopar on social media for updates.

Read more at GlobeNewswire: Monopar Presents New Data and Analyses on Rapidly Improved